Reimagining Medicine Q2 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Novartis pipeline in Phase 2
Solid Tumors
Code
AAA601
Name
Mechanism
Lutathera®
Indication(s)
Conclusions
Appendix
Innovation: Clinical trials
Hematology
Radioligand therapy target SSTR GEPNET, pediatrics
1L ES-SCLC
Glioblastoma
NSCLC and CRC (mono and/or combo)
MBG453 sabatolimab
JDQ443
JDQ443
KRAS inhibitor
NIS793
nisevokitug
TGFB inhibitor
1L metastatic colorectal cancer
TNO155 TNO155
SHP2 inhibitor
Solid tumors
Immunology
Code
Name
CFZ533
iscalimab
Mechanism
CD40 inhibitor
Indication(s)
Sjögren's
References
Abbreviations
INNOVATION
25 lead indications
Lead indication
Mechanism
BCR-ABL inhibitor
Code Name
ABL001 Scemblix®
INC424 Jakavi®
JAK1/2 inhibitor
TIM3 antagonist
PHE885 PHE885
PKC412 Rydapte
YTB323
rapcabtagene autoleucel
Cardiovascular
BCMA cell therapy
Multi-targeted kinase inhibitor.
CD19 CAR-T
Indication(s)
Chronic myeloid leukemia, 2L, pediatrics
Acute GVHD, pediatrics
Chronic GVHD, pediatrics
Unfit acute myeloid leukemia
Acute myeloid leukemia, maintenance
4L multiple myeloma
Acute myeloid leukemia, pediatrics
1L high-risk large B-cell lymphoma
Hidradenitis suppurativa
Indication(s)
CMK389 CMK389
IL-18 inhibitor
Atopic dermatitis
DFV890 DFV890
NLRP3 inhibitor
Knee osteoarthritis
Familial cold auto-inflammatory syndrome
LNA043 LNA043
ANGPTL3 agonist
Knee osteoarthritis
Osteoarthritis (combos)
LOU064
remibrutinib
BTK inhibitor
Food allergy
Hidradenitis suppurativa
Sjögren's
LRX712 LRX712
MAS825 MAS825
Osteoarthritis
Code
Name
CFZ533
LNP023
iscalimab
TIN816
iptacopan
TIN816
CFB inhibitor
ATP modulator
XXB750 XXB750
Mechanism
CD40 inhibitor
NPR1 agonist
Indication(s)
Lupus nephritis
Lupus nephritis
Acute kidney injury
Hypertension
Others
Code
IB&GH
Name
Mechanism
NLRC4-GOF indications.
KAE609 cipargamin
MHV370 MHV370
TLR7, TLR8 Antagonist
Sjögren's
Mixed connective tissue disease
KLU156
NG1226 NG1226
Tendinopathy
Ganaplacide +
lumefantrine
QUC398 QUC398
ADAMTS5 inhibitor
Osteoarthritis
LXE408
LXE408
RHH646 RHH646
Osteoarthritis
QMF149
AtecturaⓇ
VAY736 ianalumab
YTB323
BAFF-R inhibitor
CD19 CAR-T
Autoimmune hepatitis
SEG101
Adakveo®
srSLE/LN
Respiratory
rapcabtagene autoleucel
Neuroscience
Code
Name
BLZ945 sotuletinib
DLX3131 minzasolmin
MIJ821
onfasprodil
Mechanism
CSF-1R inhibitor
Alpha-synuclein Inhibitor
NR2B negative allosteric
modulator
1. DLX313 is the Novartis compound code for UCB0599.
Indication(s)
Amyotrophic lateral sclerosis
Parkinson's disease
Treatment resistant depression
Major depressive disorder with acute suicidal ideation or behavior
CMK389 CMK389
LTP001 LTP001
Ophthalmology
LNP023
PfATP4 inhibitor
Non-artemisinin plasmodium
falciparum inhibitor
Proteasome inhibitor
LABA + ICS
P-selectin inhibitor
IL-18 inhibitor
SMURF1 inhibitor
Malaria, severe
Malaria, uncomplicated
Malaria, uncomplicated
Visceral leishmaniasis
Asthma, pediatrics
Sickle cell disease, pediatrics
Pulmonary sarcoidosis
Pulmonary arterial hypertension
Idiopathic pulmonary fibrosis
iptacopan
CFB inhibitor
PPY9882 PPY988
SAF3123 Libvatrep
Gene therapy Complement
factor I modulation
TRPV1 antagonist
¡AMD
Geographic atrophy
Chronic ocular surface pain
2. Gyroscope acquisition. 3. 'Front of eye' ophthalmology divestment, subject to customary closing conditions; closing expected H2 2023.
33 Investor Relations | Q2 2023 Results
U NOVARTIS | Reimagining MedicineView entire presentation